Trial Profile
Open-label Extension Study With Tadekinig Alfa (r-hIL-18BP) to Monitor Safety and Tolerability in Patients With IL-18 Driven Monogenic Autoinflammatory Conditions: NLRC4 Mutation and XIAP Deficiency
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Nov 2023
Price :
$35
*
At a glance
- Drugs Tadekinig alfa (Primary)
- Indications Autoimmune disorders; Immunological disorders
- Focus Adverse reactions; Pharmacodynamics
- Sponsors AB2 Bio
- 07 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 02 Nov 2023 Planned End Date changed from 30 Jan 2024 to 30 May 2024.
- 02 Nov 2023 Planned primary completion date changed from 30 Nov 2023 to 30 Apr 2024.